Is It A Rash Or Photosensitivity? FDA May Have To Distinguish Them In Simeprevir Label
Executive Summary
Antiviral Drugs Advisory Committee members debated whether both adverse reactions should be included in the simeprevir label’s “Warnings and Precautions” section and whether photosensitivity should automatically lead to stopping treatment.
You may also be interested in...
Janssen’s Simeprevir May Require Hep C Subpopulation Screening
FDA advisory committee briefing documents recommend patients be screened for the Q80K polymorphism because of lower efficacy in those patients, an issue not seen with Incivek or Victrelis.
Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities
For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.